DrugEYE™, Data-driven drug discovery
DrugEYE™ provides Pharmaceutical companies, Research laboratories and Health authorities, precious foreknowledge about any emerging organism (virus, bacteria) immediately after it is detected and based on simple input. DrugEYE™ generates its output off-laboratory in a fully data driven way, saving months of wet lab research and funnelling the researcher’s efforts into the right direction.
- Functional characterization of the organism’s genes
- Prediction of the long term impacts on the human body
- Shortlist of candidate molecules to feed the drug discovery
Dynamic customer segmentation
Customer needs and expectations are changing rapidly, and traditional multi-criteria segmentation or clustering methods are no longer sufficient to act on the rapidly changing customer needs. The solutions allows to anticipate on customer needs based on a robust modelling of their behaviour and preferences, giving your company a leap ahead of the competition.
- AI inferred customer segmentation
- Automatic update of the segmentation identifying emerging customer behavioural patterns
- Ongoing recommendation engine for up-selling, cross-selling, Next Best Opportunities, Next Best Actions, best channel
Related news
MajestEYE was selected by JICA, the Japanese International Cooperation Agency, among the top 10 most innovative start-ups in Africa for its Artificial Intelligence solution DrugEYE™, which sets to disrupt the…
MajestEYE winner of the "Best Artificial Intelligence solution in e-health" competition Jihed Hannachi - Co-Founder of MajestEYE receiving the award on behalf of MajestEYE In recent weeks, the spread of…
“They were heroic” That’s what the Start’Act team said about MajestEYE along with other Tunisian startups for their contribution in their efforts in the fight against the COVID19.“The period of…
MajestEYE joins the British Telecom innovation cluster We are happy to share with you that MajestEYE has just been admitted to British Telecom (BT) Incubator, Innovation Martelsham.MajestEYE has just been…
